Abstract |
Given its approval for the treatment of cytokine release syndrome, tocilizumab is under investigation in severe coronavirus disease-2019. To characterize serious adverse events (AEs) with tocilizumab, we queried the worldwide FDA Adverse Event Reporting System and performed disproportionality analysis, selecting only designated medical events ( DMEs) where tocilizumab was reported as suspect, with a focus on hepatic reactions. The reporting odds ratios (RORs) were calculated, deemed significant by a lower limit of the 95% confidence interval (LL 95% CI) > 1. A total of 2,433 reports of DMEs were recorded with tocilizumab, mainly in rheumatic diseases. Statistically significant RORs emerged for 13 DMEs, with drug-induced liver injury (n = 91; LL 95% CI 3.07), pancreatitis (151; 1.41), and pulmonary fibrosis (222; 7.21) as unpredictable AEs. A total of 174 cases of liver-related DMEs were retrieved (proportion of deaths = 18.4%), with median onset of 27.5 days. These serious unpredictable reactions occurring in chronic real-world tocilizumab use may support patient care and monitoring of ongoing clinical trials.
|
Authors | Milo Gatti, Michele Fusaroli, Paolo Caraceni, Elisabetta Poluzzi, Fabrizio De Ponti, Emanuel Raschi |
Journal | British journal of clinical pharmacology
(Br J Clin Pharmacol)
Vol. 87
Issue 3
Pg. 1533-1540
(03 2021)
ISSN: 1365-2125 [Electronic] England |
PMID | 32639062
(Publication Type: Journal Article, Observational Study)
|
Copyright | © 2020 The British Pharmacological Society. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- tocilizumab
|
Topics |
- Adult
- Adverse Drug Reaction Reporting Systems
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized
(adverse effects, therapeutic use)
- COVID-19
(complications)
- Chemical and Drug Induced Liver Injury
(epidemiology)
- Cytokine Release Syndrome
(drug therapy, etiology)
- Databases, Factual
- Female
- Humans
- Male
- Middle Aged
- Monitoring, Physiologic
- Odds Ratio
- Pancreatitis
(chemically induced, epidemiology)
- Pharmacovigilance
- Pulmonary Fibrosis
(chemically induced, epidemiology)
- Retrospective Studies
- United States
- United States Food and Drug Administration
- Young Adult
- COVID-19 Drug Treatment
|